Cambrex looks to fill 'onshore' API manufacturing demand with $50M expansion in Iowa

URLhttps://www.fiercepharma.com/manufacturing/cambrex
SourceFierce Pharma
Date Published11/17/2020
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Cambrex
Type of work Manufacturing
Reshoring category:Reshoring
Total number of jobs (added or to be added):400
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2022
Domestically, the work will be done:In-house
Capital investment ($):50
City reshored to:Charles City
State(s) reshored to:IA
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredactive pharmaceutical ingredients
What non-domestic negative factors made offshoring less attractive?Strained offshore relationships, Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Impact on domestic economy
Find Reshoring Articles